Acumen Pharmaceuticals

Acumen Pharmaceuticals appoints Amy Schacterle, Ph.D., as Chief Regulatory Officer & Head of Quality, as the company advances its Alzheimer's disease treatment, sabirnetug, through clinical trials.

The pTau217 assay effectively screens participants for ALTITUDE-AD, reducing unnecessary amyloid PET scans and lumbar punctures.

Acumen Pharmaceuticals to present on using pTau217 assay in ALTITUDE-AD trial screening at CTAD 2024, evaluating sabirnetug for early Alzheimer’s disease.

Halozyme Therapeutics announces argenx has nominated four new targets for ENHANZE® drug delivery tech, bringing the total to six, including FcRn. argenx to pay Halozyme $30 million upfront and potential future milestone payments up to $85 million per target.

Acumen Pharmaceuticals extends collaboration with Lonza for drug product manufacturing of sabirnetug (ACU193) for early Alzheimer’s disease, building on successful drug substance manufacturing for clinical studies. Lonza will manufacture cGMP DP for ongoing and future clinical phases and support potential commercial launch at its Visp facility.

Acumen Pharmaceuticals (ABOS) focuses on Alzheimer's disease treatments, targeting toxic soluble amyloid-beta oligomers (AβOs). Their lead candidate, sabirnetug (ACU193), showed positive Phase 1 results and is advancing to Phase 2. With $296.6M in cash, Acumen is well-positioned for clinical activities into 2027.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.